Your search for mepolizumab returned 118 results

Mepolizumab was associated with improvements in asthma control and quality of life, as well as reductions in disease exacerbations in patients with comorbid severe asthma and upper airway disease.

GlaxoSmithKline announced that the primary endpoint for its Phase 3 study of mepolizumab was met for the reduction in the frequency of exacerbations, in patients with severe eosinophilic asthma.

The researchers found that the mean annual rate of moderate or severe exacerbations in the modified intention-to-treat population with an eosinophilic phenotype was 1.40 and 1.71 per year in the mepolizumab and placebo groups in METREX (rate ratio, 0.82; 95% confidence interval, 0.68 to 0.98; adjusted P=0.04).

Investigators sought to determine a link between baseline blood eosinophil counts and certain biomarkers and observed that mepolizumab-treated individuals with elevated baseline levels of eosinophil-derived neurotoxin experienced the greatest reduction in exacerbation rates.

Mepolizumab cut the rate of exacerbations requiring hospitalization and/or emergency room visit by approximately half compared to placebo in patients with severe eosinophilic asthma, according to a study published in The Journal of Allergy and Clinical Immunology.

Mepolizumab may be effective in patients with asthma that does not respond to omalizumab.

Mepolizumab reduces disease symptoms in patients with chronic rhinosinusitis with nasal polyps, according to the results of a randomized, double-blind, multicenter study.

The researchers conducted a retrospective cohort study using claims data from the Optum Research Database for 538 patients at least 6 years of age who initiated mepolizumab treatment for asthma between January 2016 and December 2019.

Mepolizumab reduced the number of exacerbations in patients with severe asthma, but exacerbations per month remained relatively stable throughout the year without a clear seasonal influence.

Data mining resulted in 2006 reports of anaphylaxis related to the use of 5 mAbs.